Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome

Abstract Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogenesis. Proton pump inhibitors (PPIs) have b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shiori Hiromoto, Takehiro Kawashiri, Natsumi Yamanaka, Daisuke Kobayashi, Keisuke Mine, Mizuki Inoue, Mayako Uchida, Takao Shimazoe
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/edd08d6edf7b40e8b4966dce32425657
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:edd08d6edf7b40e8b4966dce32425657
record_format	dspace
spelling	oai:doaj.org-article:edd08d6edf7b40e8b4966dce324256572021-12-02T17:39:20ZUse of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome10.1038/s41598-021-88460-92045-2322https://doaj.org/article/edd08d6edf7b40e8b4966dce324256572021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88460-9https://doaj.org/toc/2045-2322Abstract Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogenesis. Proton pump inhibitors (PPIs) have been reported to have anti-inflammatory effects. In this study, we investigated the ameliorative effects of omeprazole, a PPI on capecitabine-related HFS in mice model, and a real-world database. Repeated administration of capecitabine (200 mg/kg, p.o., five times a week for 3 weeks) increased fluid content, redness, and tumor necrosis factor (TNF)-α substance of the mice hind paw. Co-administration of omeprazole (20 mg/kg, p.o., at the same schedule) significantly inhibited these changes induced by capecitabine. Moreover, based on the clinical database analysis of the Food and Drug Administration Adverse Event Reporting System, the group that has used any PPIs had a lower reporting rate of capecitabine-related PPE than the group that has not used any PPIs. (6.25% vs. 8.31%, p < 0.0001, reporting odds ratio (ROR) 0.74, 95% confidence interval (CI) 0.65–0.83). Our results suggest that omeprazole may be a potential prophylactic agent for capecitabine-induced HFS.Shiori HiromotoTakehiro KawashiriNatsumi YamanakaDaisuke KobayashiKeisuke MineMizuki InoueMayako UchidaTakao ShimazoeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shiori Hiromoto Takehiro Kawashiri Natsumi Yamanaka Daisuke Kobayashi Keisuke Mine Mizuki Inoue Mayako Uchida Takao Shimazoe Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
description	Abstract Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogenesis. Proton pump inhibitors (PPIs) have been reported to have anti-inflammatory effects. In this study, we investigated the ameliorative effects of omeprazole, a PPI on capecitabine-related HFS in mice model, and a real-world database. Repeated administration of capecitabine (200 mg/kg, p.o., five times a week for 3 weeks) increased fluid content, redness, and tumor necrosis factor (TNF)-α substance of the mice hind paw. Co-administration of omeprazole (20 mg/kg, p.o., at the same schedule) significantly inhibited these changes induced by capecitabine. Moreover, based on the clinical database analysis of the Food and Drug Administration Adverse Event Reporting System, the group that has used any PPIs had a lower reporting rate of capecitabine-related PPE than the group that has not used any PPIs. (6.25% vs. 8.31%, p < 0.0001, reporting odds ratio (ROR) 0.74, 95% confidence interval (CI) 0.65–0.83). Our results suggest that omeprazole may be a potential prophylactic agent for capecitabine-induced HFS.
format	article
author	Shiori Hiromoto Takehiro Kawashiri Natsumi Yamanaka Daisuke Kobayashi Keisuke Mine Mizuki Inoue Mayako Uchida Takao Shimazoe
author_facet	Shiori Hiromoto Takehiro Kawashiri Natsumi Yamanaka Daisuke Kobayashi Keisuke Mine Mizuki Inoue Mayako Uchida Takao Shimazoe
author_sort	Shiori Hiromoto
title	Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
title_short	Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
title_full	Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
title_fullStr	Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
title_full_unstemmed	Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
title_sort	use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/edd08d6edf7b40e8b4966dce32425657
work_keys_str_mv	AT shiorihiromoto useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome AT takehirokawashiri useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome AT natsumiyamanaka useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome AT daisukekobayashi useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome AT keisukemine useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome AT mizukiinoue useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome AT mayakouchida useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome AT takaoshimazoe useofomeprazoletheprotonpumpinhibitorasapotentialtherapyforthecapecitabineinducedhandfootsyndrome
_version_	1718379856405725184

Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome

Ejemplares similares